HS 10370
Alternative Names: HS-10370Latest Information Update: 14 May 2025
At a glance
- Originator Jiangsu Hansoh Pharmaceutical
- Class Antineoplastics; Small molecules
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 09 May 2025 Jiangsu Hansoh Pharmaceutical plans a phase Ib trial in Solid tumours (Late-stage disease, Combination therapy, Metastatic disease) in China (IV) in May 2025 (NCT06963502)
- 25 Apr 2025 Adverse events and efficacy data from a phase I/II trial in Solid tumours presented 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 19 Sep 2024 Jiangsu Hansoh Pharmaceutical plans a phase Ib trial in Solid tumours (Late-stage disease, Combination therapy, Inoperable/unresectable, Metastatic disease) in China in October 2024 (PO) (NCT06594874)